Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Randomized Controlled Trial of Suzetrigine as an Adjunct to Multimodal Analgesia Following Total Knee Arthroplasty

NCT07928011 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT07928011 Not yet recruiting Phase 4 40 participants (estimated) Started 2027 1 site

Follow this trial by email Email me the PDF

Get the NCT07928011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started January 2027. Interventional study, Phase 4, 40 participants (estimated). Lead sponsor University of California, Irvine; United States. Primary measures: Participant enrollment; Protocol adherence and 1 more.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Randomized Controlled Trial of Suzetrigine as an Adjunct to Multimodal Analgesia Following Total Knee Arthroplasty
Lead sponsor
University of California, Irvine
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
April 30, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them.

total knee arthroplasty

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Maximum age
80 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
United States
Lead sponsor
University of California, Irvine

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Standard Multimodal Group No intervention
Show registry wording

Standard multimodal control group will receive treatment components such as nerve block through an adductor canal catheter for 4 days, cryotherapy/icing as needed, scheduled non-opioid drug (acetaminophen 1000 mg 3 times a day), nonsteroidal anti-inflammatory drug (NSAID) (Meloxicam 15mg daily), and breakthrough opioid (Oxycodone 5mg every 4 hours as needed).

Suzetrigine Group Experimental Suzetrigine
Show registry wording

The Suzetrigine group will receive a 100 mg loading dose of Suzetrigine, followed by 50mg Q12h for 14 days as an addition to a standardized multimodal pain management pathway. The standardized multimodal pain management pathway consists of treatment components such as nerve block through an adductor canal catheter for 4 days, cryotherapy/icing as needed, scheduled non-opioid drug (acetaminophen 1000 mg 3 times a day), nonsteroidal anti-inflammatory drug (NSAID) (Meloxicam 15mg daily), and breakthrough opioid (Oxycodone 5mg every 4 hours as needed).

Primary endpoints

Registered primary outcome measures; 3 primary.

Registered primary endpoints
Measure Time frame
Participant enrollment At enrollment
Show registry wording

Enrollment rates

Protocol adherence Within 14 days
Show registry wording

Protocol adherence rates

Data collection At 14 days
Show registry wording

Completeness of data collection

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Suzetrigine 1 Orange Book patentPatent cliff December 4, 2040 (Orange Book patent)
    • US 11834441; expires December 4, 2040; assignee Vertex Pharmaceuticals Inc / Ma

Lead sponsor's other trials

University of California, Irvine, most recent start first.